+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global Overactive Bladder Treatment Market by Drug Therapy (Anticholinergic, BOTO, Darifenacin), Disease Type (Idiopathic Bladder Overactivity, Neurogenic Bladder Overactivity), Distribution - Forecast 2024-2030- Product Image
Global Overactive Bladder Treatment Market by Drug Therapy (Anticholinergic, BOTO, Darifenacin), Disease Type (Idiopathic Bladder Overactivity, Neurogenic Bladder Overactivity), Distribution - Forecast 2024-2030- Product Image
Sale

Global Overactive Bladder Treatment Market by Drug Therapy (Anticholinergic, BOTO, Darifenacin), Disease Type (Idiopathic Bladder Overactivity, Neurogenic Bladder Overactivity), Distribution - Forecast 2024-2030

  • PDF Icon

    Report

  • 194 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 4968613
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Overactive Bladder Treatment Market size was estimated at USD 4.54 billion in 2023, USD 4.71 billion in 2024, and is expected to grow at a CAGR of 3.74% to reach USD 5.88 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Overactive Bladder Treatment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Overactive Bladder Treatment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Overactive Bladder Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Allergan plc, Astellas Pharma Inc., Cipla Limited, DETROL LA by Viatris Company, Endo International plc, Granules India Limited, Hisamitsu Pharmaceutical Co., Inc., Medtronic plc, Mylan N.V., Pfizer Inc., Sunovion Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Urovant Sciences Inc., and Zydus Lifesciences Limited.

Market Segmentation & Coverage

This research report categorizes the Overactive Bladder Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug Therapy
    • Anticholinergic
    • BOTO
    • Darifenacin
    • Fesoterodine
    • Mirabegron
    • Neurostimulation
    • Oxybutynin
    • Solifenacin
  • Disease Type
    • Idiopathic Bladder Overactivity
    • Neurogenic Bladder Overactivity
  • Distribution
    • Hospital & Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast of the Overactive Bladder Treatment Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Overactive Bladder Treatment Market?
  3. What are the technology trends and regulatory frameworks in the Overactive Bladder Treatment Market?
  4. What is the market share of the leading vendors in the Overactive Bladder Treatment Market?
  5. Which modes and strategic moves are suitable for entering the Overactive Bladder Treatment Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Overactive Bladder Treatment Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growth in number of people with overactive bladder (OAB) symptoms
5.1.1.2. Increase in aging population
5.1.2. Restraints
5.1.2.1. Adverse effects and risk associated with overactive bladder treatment
5.1.3. Opportunities
5.1.3.1. Overactive bladder clinical research trials and pipeline
5.1.4. Challenges
5.1.4.1. Limited awareness of OAB condition
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Overactive Bladder Treatment Market, by Drug Therapy
6.1. Introduction
6.2. Anticholinergic
6.3. BOTO
6.4. Darifenacin
6.5. Fesoterodine
6.6. Mirabegron
6.7. Neurostimulation
6.8. Oxybutynin
6.9. Solifenacin
7. Overactive Bladder Treatment Market, by Disease Type
7.1. Introduction
7.2. Idiopathic Bladder Overactivity
7.3. Neurogenic Bladder Overactivity
8. Overactive Bladder Treatment Market, by Distribution
8.1. Introduction
8.2. Hospital & Hospital Pharmacies
8.3. Online Pharmacies
8.4. Retail Pharmacies
9. Americas Overactive Bladder Treatment Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Overactive Bladder Treatment Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Overactive Bladder Treatment Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. AbbVie Inc.
13.1.2. Allergan plc
13.1.3. Astellas Pharma Inc.
13.1.4. Cipla Limited
13.1.5. DETROL LA by Viatris Company
13.1.6. Endo International plc
13.1.7. Granules India Limited
13.1.8. Hisamitsu Pharmaceutical Co., Inc.
13.1.9. Medtronic plc
13.1.10. Mylan N.V.
13.1.11. Pfizer Inc.
13.1.12. Sunovion Pharmaceuticals Inc.
13.1.13. Teva Pharmaceutical Industries Ltd.
13.1.14. Urovant Sciences Inc.
13.1.15. Zydus Lifesciences Limited
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
List of Figures
FIGURE 1. OVERACTIVE BLADDER TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. OVERACTIVE BLADDER TREATMENT MARKET SIZE, 2023 VS 2030
FIGURE 3. OVERACTIVE BLADDER TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. OVERACTIVE BLADDER TREATMENT MARKET DYNAMICS
FIGURE 7. OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2023 VS 2030 (%)
FIGURE 8. OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
FIGURE 10. OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
FIGURE 12. OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. OVERACTIVE BLADDER TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. OVERACTIVE BLADDER TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
List of Tables
TABLE 1. OVERACTIVE BLADDER TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. OVERACTIVE BLADDER TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 6. OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ANTICHOLINERGIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BOTO, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DARIFENACIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY FESOTERODINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY MIRABEGRON, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NEUROSTIMULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY OXYBUTYNIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY SOLIFENACIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 15. OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY IDIOPATHIC BLADDER OVERACTIVITY, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NEUROGENIC BLADDER OVERACTIVITY, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 18. OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY HOSPITAL & HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. AMERICAS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 22. AMERICAS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 23. AMERICAS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 24. AMERICAS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 25. ARGENTINA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 26. ARGENTINA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 27. ARGENTINA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 28. BRAZIL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 29. BRAZIL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 30. BRAZIL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 31. CANADA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 32. CANADA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 33. CANADA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 34. MEXICO OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 35. MEXICO OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 36. MEXICO OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 37. UNITED STATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 38. UNITED STATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 39. UNITED STATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 40. UNITED STATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 41. ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 42. ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 43. ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 44. ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 45. AUSTRALIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 46. AUSTRALIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 47. AUSTRALIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 48. CHINA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 49. CHINA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 50. CHINA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 51. INDIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 52. INDIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 53. INDIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 54. INDONESIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 55. INDONESIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 56. INDONESIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 57. JAPAN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 58. JAPAN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 59. JAPAN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 60. MALAYSIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 61. MALAYSIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 62. MALAYSIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 63. PHILIPPINES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 64. PHILIPPINES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 65. PHILIPPINES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 66. SINGAPORE OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 67. SINGAPORE OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 68. SINGAPORE OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 69. SOUTH KOREA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 70. SOUTH KOREA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 71. SOUTH KOREA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 72. TAIWAN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 73. TAIWAN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 74. TAIWAN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 75. THAILAND OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 76. THAILAND OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 77. THAILAND OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 78. VIETNAM OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 79. VIETNAM OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 80. VIETNAM OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 83. EUROPE, MIDDLE EAST & AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 84. EUROPE, MIDDLE EAST & AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 85. DENMARK OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 86. DENMARK OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 87. DENMARK OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 88. EGYPT OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 89. EGYPT OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 90. EGYPT OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 91. FINLAND OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 92. FINLAND OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 93. FINLAND OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 94. FRANCE OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 95. FRANCE OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 96. FRANCE OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 97. GERMANY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 98. GERMANY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 99. GERMANY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 100. ISRAEL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 101. ISRAEL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 102. ISRAEL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 103. ITALY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 104. ITALY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 105. ITALY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 106. NETHERLANDS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 107. NETHERLANDS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 108. NETHERLANDS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 109. NIGERIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 110. NIGERIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 111. NIGERIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 112. NORWAY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 113. NORWAY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 114. NORWAY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 115. POLAND OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 116. POLAND OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 117. POLAND OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 118. QATAR OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 119. QATAR OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 120. QATAR OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 121. RUSSIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 122. RUSSIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 123. RUSSIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 124. SAUDI ARABIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 125. SAUDI ARABIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 126. SAUDI ARABIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 127. SOUTH AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 128. SOUTH AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 129. SOUTH AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 130. SPAIN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 131. SPAIN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 132. SPAIN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 133. SWEDEN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 134. SWEDEN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 135. SWEDEN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 136. SWITZERLAND OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 137. SWITZERLAND OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 138. SWITZERLAND OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 139. TURKEY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 140. TURKEY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 141. TURKEY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 142. UNITED ARAB EMIRATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 143. UNITED ARAB EMIRATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 144. UNITED ARAB EMIRATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 145. UNITED KINGDOM OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
TABLE 146. UNITED KINGDOM OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 147. UNITED KINGDOM OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 148. OVERACTIVE BLADDER TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 149. OVERACTIVE BLADDER TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
TABLE 150. OVERACTIVE BLADDER TREATMENT MARKET LICENSE & PRICING

Companies Mentioned

  • AbbVie Inc.
  • Allergan plc
  • Astellas Pharma Inc.
  • Cipla Limited
  • DETROL LA by Viatris Company
  • Endo International plc
  • Granules India Limited
  • Hisamitsu Pharmaceutical Co., Inc.
  • Medtronic plc
  • Mylan N.V.
  • Pfizer Inc.
  • Sunovion Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Urovant Sciences Inc.
  • Zydus Lifesciences Limited

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages194
PublishedMarch 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 4.71 Billion
Forecasted Market Value ( USD ) by 2030 $ 5.88 Billion
Compound Annual Growth Rate3.7%
Regions CoveredGlobal
No. of Companies Mentioned15

Related Topics

Related Reports

Global Overactive Bladder Treatment Market Size, Share & Trends Analysis Report, Type (Anticholinergics, Mirabegron, Neuromodulation, Botox), Disease Type (Idiopathic, Neurogenic), Distribution Channel, Region, and Segment Forecasts, 2024-2030 - Product Image

Global Overactive Bladder Treatment Market Size, Share & Trends Analysis Report, Type (Anticholinergics, Mirabegron, Neuromodulation, Botox), Disease Type (Idiopathic, Neurogenic), Distribution Channel, Region, and Segment Forecasts, 2024-2030

  • Report
  • 100 Pages
  • Global
From
Overactive Bladder Treatment Global Market Report 2024 - Product Image

Overactive Bladder Treatment Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From
Overactive Bladder Treatment Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application - Product Image

Overactive Bladder Treatment Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application

  • Report
  • 96 Pages
  • Global
From
Overactive Bladder (OAB) Therapeutics: Global Strategic Business Report - Product Image

Overactive Bladder (OAB) Therapeutics: Global Strategic Business Report

  • Report
  • 271 Pages
  • Global
From
2023 Global Forecast for Overactive Bladder Treatment Market (2024-2029 Outlook) - High Tech & Emerging Markets Report - Product Image

2023 Global Forecast for Overactive Bladder Treatment Market (2024-2029 Outlook) - High Tech & Emerging Markets Report

  • Report
  • 132 Pages
  • Global
From

About the Overactive Bladder Drug Market

The Overactive Bladder Drug market is a subset of the Urological Disorders Drugs market. It is composed of drugs used to treat overactive bladder, a condition characterized by frequent urination, urgency, and incontinence. These drugs work by relaxing the bladder muscles, reducing the urge to urinate, and improving bladder control. Commonly used drugs include anticholinergics, beta-3 agonists, and muscarinic receptor antagonists. These drugs are available in both oral and topical formulations. The Overactive Bladder Drug market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include Pfizer, Astellas Pharma, Allergan, Merck, Sanofi, and GlaxoSmithKline. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.